Profund Advisors LLC Acquires 42,379 Shares of uniQure N.V. $QURE

Profund Advisors LLC raised its stake in shares of uniQure N.V. (NASDAQ:QURE) by 248.1% during the fourth quarter, Holdings Channel reports. The firm owned 59,463 shares of the biotechnology company’s stock after buying an additional 42,379 shares during the period. Profund Advisors LLC’s holdings in uniQure were worth $1,423,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in uniQure by 15.7% in the 3rd quarter. Vanguard Group Inc. now owns 1,125,108 shares of the biotechnology company’s stock valued at $65,673,000 after buying an additional 152,417 shares in the last quarter. Aberdeen Group plc raised its stake in uniQure by 6.9% during the third quarter. Aberdeen Group plc now owns 2,939,743 shares of the biotechnology company’s stock worth $171,593,000 after acquiring an additional 189,029 shares in the last quarter. Quinn Opportunity Partners LLC acquired a new position in uniQure during the third quarter worth $6,281,000. Farallon Capital Management LLC lifted its holdings in shares of uniQure by 3,935.7% during the third quarter. Farallon Capital Management LLC now owns 565,000 shares of the biotechnology company’s stock valued at $32,979,000 after acquiring an additional 551,000 shares during the period. Finally, Darwin Global Management Ltd. bought a new position in shares of uniQure during the third quarter valued at $23,760,000. 78.83% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on QURE. Chardan Capital upped their target price on shares of uniQure from $31.00 to $37.00 and gave the stock a “buy” rating in a report on Thursday, April 30th. Mizuho upgraded shares of uniQure from a “neutral” rating to an “outperform” rating and boosted their price target for the company from $12.00 to $35.00 in a research report on Wednesday, March 11th. Barclays decreased their price objective on shares of uniQure from $31.00 to $25.00 and set an “equal weight” rating on the stock in a research note on Monday, March 23rd. Stifel Nicolaus set a $28.00 price objective on shares of uniQure in a report on Tuesday, May 5th. Finally, Cantor Fitzgerald reiterated a “neutral” rating and issued a $9.00 target price (down from $55.00) on shares of uniQure in a research note on Monday, March 2nd. Ten equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, uniQure has an average rating of “Moderate Buy” and an average target price of $42.83.

Insider Activity at uniQure

In other uniQure news, CFO Christian Klemt sold 12,000 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $9.06, for a total value of $108,720.00. Following the transaction, the chief financial officer directly owned 226,581 shares in the company, valued at approximately $2,052,823.86. This trade represents a 5.03% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Walid Abi-Saab sold 45,000 shares of uniQure stock in a transaction on Friday, May 8th. The shares were sold at an average price of $25.06, for a total value of $1,127,700.00. Following the completion of the sale, the insider directly owned 169,669 shares of the company’s stock, valued at $4,251,905.14. This trade represents a 20.96% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 94,396 shares of company stock valued at $1,850,434 over the last three months. 4.79% of the stock is owned by company insiders.

uniQure Stock Performance

uniQure stock opened at $24.60 on Thursday. The stock has a 50-day simple moving average of $18.94 and a 200 day simple moving average of $22.33. The stock has a market capitalization of $1.55 billion, a price-to-earnings ratio of -7.07 and a beta of 0.87. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure N.V. has a 12-month low of $8.73 and a 12-month high of $71.50.

uniQure (NASDAQ:QURE) last issued its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The firm had revenue of $3.56 million for the quarter, compared to analyst estimates of $5.21 million. On average, research analysts anticipate that uniQure N.V. will post -3.68 earnings per share for the current fiscal year.

uniQure Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.